首页|中药调控AGE-RAGE信号通路治疗多囊卵巢综合征的研究现状

中药调控AGE-RAGE信号通路治疗多囊卵巢综合征的研究现状

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
多囊卵巢综合征(PCOS)是妇科常见的内分泌代谢性疾病,临床主要表现为不孕、多毛、肥胖、月经紊乱等,严重影响女性健康.中药治疗PCOS的作用机制涉及多种信号通路,其中晚期糖基化终产物-晚期糖基化终末产物受体(AGE-RAGE)信号通路是一条调控炎症和氧化应激的重要通路,越来越多的中药复方、单味中药及其提取物可以通过调控AGE-RAGE信号通路降低患者体内炎症反应、氧化应激、胰岛素抵抗和高雄激素血症等,为治疗PCOS提供了新的策略与方向.但目前缺乏中药干预AGE-RAGE信号通路治疗PCOS全面的总结,故本文对近年来中药调控该信号通路治疗PCOS的研究现状进行综述,以期为进一步研究PCOS提供新的方向和思考.
Research progress of Chinese medicine regulating AGE-RAGE signaling pathway in the treatment of polycystic ovary syndrome
Polycystic ovary syndrome(PCOS)is a common endocrine and metabolic disease in gynecology.The main clinical manifestations are infertility,hirsuty,obesity,menstrual disorders,etc.,which seriously affect women's health.Studies have shown that the mechanism of action of traditional Chinese medicine in the treatment of PCOS involves a variety of signaling pathways,among which advanced glycation end products-receptor for advanced glycation end products(AGE-RAGE)signaling pathway is an important pathway regulating inflammation and oxidative stress.More and more Chinese herbal compounds,single herbs and their extracts can reduce inflammation,oxidative stress,insulin resistance and hyperandrogenemia in patients by regulating AGE-RAGE signaling pathway,which provides a new strategy and direction for the treatment of PCOS.However,there is currently no comprehensive summary of Chinese medicine intervention in the treatment of PCOS by AGE-RAGE signaling pathway.Therefore,this paper reviews the current research status of Chinese medicine regulation of AGE-RAGE signaling pathway in the treatment of PCOS in recent years,so as to provide new directions and thoughts for further research on PCOS.

traditional Chinese medicinepolycystic ovary syndromeadvanced glycation end products-receptor for advanced glycation end products signaling pathwaytreatment

冉冰清、黄进格、吴月娟、王芳

展开 >

甘肃中医药大学中西医结合临床医学院,甘肃兰州 730000

兰州大学第二医院生殖医学科,甘肃兰州 730030

中药 多囊卵巢综合征 晚期糖基化终产物-晚期糖基化终末产物受体信号通路 治疗

兰州大学第二医院"萃英科技创新"基金资助项目

CY2022-MSB03

2024

10.13699/j.cnki.1001-6821.2024.17.029

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子：1.91
ISSN：1001-6821
年,卷(期)：2024.40(17)